ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements
Sai Parenterals held its 25th Annual General Meeting on September 10, 2026. Shareholders approved financial statements, director appointments, and various company resolutions.
Management is pivoting to acquisitions after regulatory shifts blocked organic expansion in Hyderabad. While revenue growth appears strong due to the Numed consolidation, margins were hurt by high logistics costs in Australia.
Sai Parenterals is transitioning from a domestic-focused player to an export-driven CDMO/branded generic platform through major acquisitions and capacity expansion. Q1 FY27 presentation focuses on IPO proceeds variation and global accreditation strategy.
Sai Parenterals Ltd reported revenue from operations of ₹178.7 Cr (+435.0% YoY) and net profit of ₹7.9 Cr (+464.3% YoY) for Q1 FY27.
Sai Parenterals reports transformational FY26 following the Noumed acquisition. Focus shifts from asset building to monetization through vertical integration and expanding the CDMO export business.
Sai Parenterals reports Q4 FY26 consolidated revenue of ₹198cr and EBITDA of ₹29cr, following the Noumed acquisition. Standalone FY26 PAT grew 64% YoY.
Sai Parenterals Ltd reported revenue from operations of ₹96.2 Cr and a net loss of ₹6.7 Cr for Q3 FY26.